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Background. Respiratory syncytial virus infection can cause lower respiratory tract infection in older adults comparable to 
influenza, but no vaccines are available.
Methods. This was a randomized, observer-blinded, first-in-humans study of a novel synthetic RSV antigen based on the ect-
odomain of the small hydrophobic glycoprotein (SHe) of RSV subgroup A, formulated with either the lipid and oil–based vaccine 
platform DepoVax (DPX-RSV[A]) or alum (RSV[A]-Alum), in healthy, 50–64-year-old individuals. Two dose levels (10 or 25 µg) of 
SHe with each formulation were compared to placebo. A booster dose was administered on day 56.
Results. There was no indication that the vaccine was unsafe. Mild pain, drowsiness, and muscles aches were the most com-
mon solicited adverse events (AEs), and the frequencies of the AEs did not increase after dose 2. Robust anti-SHe–specific immune 
responses were demonstrated in the DPX-RSV(A) 10-μg and 25-μg groups (geometric mean titer, approximately 10-fold and 100-
fold greater than that of placebo at days 56 and 236, respectively), and responses were sustained in the DPX-RSV(A) 25-μg group at 
day 421. Responses to the RSV(A)-Alum vaccines were very low.
Conclusions. A novel antigen from the SH protein of RSV, formulated in a lipid and oil–based vaccine platform, was highly 
immunogenic, with sustained antigen-specific antibody responses, and had an acceptable safety profile.
Keywords. Respiratory syncytial virus vaccines; aged; adult; immunization; vaccine immunogenicity; vaccines; inactivated 
vaccines; adjuvant.
 
Respiratory syncytial virus (RSV) is increasingly recognized as 
an acute lower respiratory tract pathogen that causes significant 
illness throughout life. Bronchiolitis and pneumonia are the 
most common cause of childhood respiratory tract infection 
worldwide [1]. In immunocompromised adults, RSV may cause 
life-threatening pneumonia [2], and in healthy older adults or 
those with cardiac or pulmonary disease, RSV infection is asso-
ciated with use of health services at a level similar to that for 
seasonal influenza [3]. The mean rate of RSV-associated hospi-
talization in older adults was 55.3 events/100 000 person-years 
(95% confidence interval [CI], 44.4–107) between 1993 and 
2008, compared with 63.5 events/100 000 person-years (95% 
CI, 37.5–237) for influenza [4]. In a retrospective cohort of 607 
RSV-infected hospitalized adults, supplemental oxygen and 
ventilatory support were required in 67.9% and 11.1%, respec-
tively, and lower respiratory tract complications occurred in 
71.9% [5].
No prophylactic antivirals or vaccines are currently available 
to prevent RSV infection in adults. At least 6 RSV vaccine candi-
dates directed at older adults are in development, predominantly 
based on the fusion transmembrane RSV protein, including a 
nanoparticle vaccine [6], a subunit nasally administered vac-
cine, and vector-delivered and live attenuated vaccines [7], all 
of which are presumed to act through antibody-mediated virus 
neutralization. We previously reported that a vaccine targeting 
the ectodomain of the RSV subgroup A surface small hydropho-
bic glycoprotein (SHe) can induce protection against intranasal 
RSV challenge in mice and cotton rats [8]. SHe-vaccinated ani-
mals had reduced pulmonary replication of RSV as compared to 
controls. Further, SHe-specific antibodies were detected bound 
to the surface of RSV-infected cells. Protection in these models 
was demonstrated to be dependent on Fcγ receptor activation 
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and resident alveolar macrophages. Thus, it was proposed that 
SHe-specific immunoglobulin G (IgG) control RSV replica-
tion by instructing alveolar macrophages to clear RSV-infected 
cells by phagocytosis. RSV vaccines for the older adult popula-
tion must be sufficiently immunogenic to overcome age-related 
changes in the innate and adaptive immune systems [9]. Vaccine 
adjuvants copresented with the RSV antigen could improve the 
immunogenicity of RSV vaccine in older persons. In this first-
in-humans study, we evaluated the safety and immunogenic-
ity of a depot-based lipid-in-oil delivery platform containing a 
novel antigenic target, SHe, in adults 50–64 years of age.
METHODS
This was a randomized, placebo-controlled, observer-blinded, 
first-in-humans, phase 1 clinical trial to evaluate the safety and 
reactogenicity of a 2-dose schedule of 4 formulations of an adju-
vanted RSV vaccine, compared with placebo, in 50–64-year-old 
healthy persons at 1 site in Canada (Figure 1). The study was 
conducted in 2 sequential steps to permit dose escalation, with 
participants randomized at ratios of 2:2:1 in both steps. The 
study was initiated on 30 June 2015, and the final (day 421) visit 
was 13 March 2017.
The study (clinical trials registration NCT02472548) was 
undertaken in compliance with Good clinical practice guide-
lines, the Declaration of Helsinki, and national regulatory 
requirements and was approved by the local institutional review 
board. An independent data safety monitoring committee 
reviewed safety data 28 days after each vaccine dose and immu-
nogenicity results after step 1.
Participants
Participants were 50–64  years of age; were healthy, based on 
medical history, clinical examination, and hematological and 
biochemical values; and had given informed written consent. 
Exclusion criteria included human immunodeficiency virus 
infection; hepatitis B or C virus infection; personal or family 
history of immunocompromise; autoimmune disease or malig-
nancy; receipt of RSV vaccine, immunoglobulins, or blood 
products within the past 3 months; or hypersensitivity to any 
vaccine component. No vaccines were permitted within 28 days 
of study vaccine receipt, except for influenza vaccine (which 
was permitted ≥15 days before study vaccination). Women of 
childbearing potential had to have a negative result of a preg-
nancy test on the day of immunization and had to practice 
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Figure 1. Participant flow through the study. See “Methods” for a description of vaccine formulations. DPX, DepoVax; RSV(A), respiratory syncytial virus subgroup A. aPar-
ticipants in the RSV(A)-Alum group received placebo on day 56, rather than RSV(A)-Alum. bOne subject was withdrawn by the investigators because of an adverse event.
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adequate contraception for 30  days before and 180  days after 
vaccine receipt.
Vaccines
The RSV(A) antigen is a 23–amino acid synthetic peptide 
(NKLCEYNVFHNKTFELPRARVNT) representing the SH ect-
odomain of RSV(A) and was synthesized by PolyPeptide Group 
(San Diego, CA). The obtained peptide powder was dimerized 
before vaccine formulation by dissolution in a solution of water, 
dimethyl sulfoxide, and acetic acid (89.5:10:1 w/w/w) and 
heating at 37°C overnight. Dimer formation was confirmed by 
high-pressure liquid chromatography and liquid chromatogra-
phy–mass spectrometry analysis.
The SHe peptide (10 or 25  μg) was formulated in DPX, a 
synthetic lipopeptide adjuvant, which is a lipid mixture of cho-
lesterol and phosphatidylcholine, and Montanide ISA 51 VG 
(Seppic, France). The DPX-RSV(A) vaccine was supplied in 
2 vials. Vial 1 contained the antigen and adjuvant system lyo-
philized to a dry cake and was stored at −20°C. It was thawed 
to room temperature on the day of vaccination and then mixed 
with vial 2, containing Montanide. The reconstituted vaccine 
appeared as a clear suspension.
The RSV(A)-Alum vaccine consisted of the SHe dimer 
and the mineral adjuvant aluminum hydroxide (Alhydrogel, 
2% colloidal suspension; Brenntag Biosector, Denmark) and 
was supplied in 2 vials. Vial 1, containing the SHe peptide 
in sodium acetate buffer, was stored at −20°C and thawed 
to room temperature on the day of vaccination. It was then 
mixed with 50  μg of alum from vial 2.  The reconstituted 
RSV(A)-Alum vaccine was hazy in appearance. The placebo 
was normal saline (0.9% sodium chloride) and was clear in 
appearance.
An unblinded pharmacist prepared vaccines at room tem-
perature on the day of immunization. An obscuring label 
with the study number was affixed to the prepared vial. An 
unblinded nurse administered study vaccines (dose volume, 
0.05 mL [50 µL]) in the deltoid. The first dose was given in the 
nondominant arm and the second dose was given in the con-
tralateral arm.
Study Procedures
After individuals provided consent to participate, screening- 
eligible participants attended visit 1 within 30 days. A step-spe-
cific randomization list was computer generated in 3 stages, 
corresponding to the staggered injection of participants over 
time. The first 3 participants in each step were randomly 
assigned in a ratio of 1:1:1 to receive 10  µg of DPX-RSV(A), 
10  µg of RSV(A)-Alum, or placebo, and the remaining 17 
subjects were randomly assigned in a ratio of 7:7:3 to receive 
DPX-RSV(A) vaccine, RSV(A)-Alum, or placebo, to achieve an 
overall randomization ratio of 2:2:1. The same process occurred 
for step 2, with the RSV(A) antigen dose increased to 25 μg.
Participants stayed in their assigned group for the booster 
dose. Per protocol, the second dose in the RSV(A)-Alum groups 
was homologous vaccine or placebo, depending on the blinded 
day 28 serologic test results for the group. If no anti-SHe anti-
bodies were detected in the day 28 serologic analysis of any 
participant in any vaccine group, then participants received 
a homologous booster dose on day 56. If anti-SHe antibodies 
were detected in any participant in any group in day 28 sero-
logic tests, then the RSV(A)-Alum group would receive pla-
cebo on day 56. This precautionary measure was taken because 
a preclinical study showed that some RSV(A)-Alum recipi-
ents had adverse reactions in the first hour after receiving the 
booster dose [10]; this reaction did not occur in DPX-RSV(A) 
recipients.
Participants attended the study site at the screening visit and 
0, 7, 28, 56, 63, 84, and 236 days later (8 visits). Participants in 
step 2 attended a ninth visit on day 421.
Outcome Measurement
Safety and Reactogenicity
The primary objective was to measure safety and reacto-
genicity from vaccination to day 28 after the first injection. 
A secondary objective was to determine safety and reactoge-
nicity up to 180 days after the second injection. The adverse 
event (AE) outcomes and severity-grading scheme are pre-
sented in Supplementary Table 1. Hematologic, biochemical, 
and screening serologic analyses were performed at the IWK 
Health Centre, using standard methods and local reference 
ranges.
Immunogenicity
Other secondary objectives of the study were to evaluate the 
immunogenicity of study vaccines 7 and 28 days after receipt 
of 1 and 2 doses of vaccine and the persistence of immune 
responses up to 180 days after the second vaccination. In step 
2 participants (ie, those who received a higher antigen dose), 
immunogenicity at day 421 was measured.
End point enzyme-linked immunosorbent assays (ELISAs) 
were done at the Immunovaccine laboratories (Halifax, Canada) 
to measure anti–SHe antibody levels, using SHe antigen. Each 
subject’s serum sample was evaluated in 5 replicates on the same 
plate as the matched day 0 serum sample, itself in 3 replicates, 
to establish a cutoff, using the day 0 absorbance. The ELISA 
results are expressed as end point titrations calculated using the 
method described by Frey et al [11].
Binding of Human IgG to Cells Expressing RSV SH
Human embryonic kidney HEK293T cells (a gift from 
Dr M.  Hall) were maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% heat-inactivated fetal calf 
serum, 1% penicillin, 1% streptomycin, 2 mM glutamine, and 
1 mM sodium pyruvate at 37°C in the presence of 5% carbon 
dioxide.
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The SH expression plasmid was constructed by amplifying 
SHe complementary DNA from complementary DNA obtained 
from total RNA derived from Hep-2 cells (CCL-23; ATCC, 
Rockville, MD) that had been infected with RSV A2 (VR-1540; 
ATCC). The primers were ATAAGAAAGCGGGCCGCTAT
GGAAAATACATCCATAACAATAG  and GAAGATCTCTA 
TGTGTTGACTCGAGCTCTTGGTAACTCAAA. The result-
ing polymerase chain reaction fragment was cloned as a NotI/
BglII fragment in the pCAGGS expression vector.
For flow cytometry, HEK293T cells were transfected with the 
RSV A2 SH expression vector in combination with a promot-
er-driven enhanced green fluorescent protein (GFP) transfec-
tion vector, using the Fugene transfection reagent (Promega). 
Forty-eight hours after transfection, the cells were detached 
using ice-cold ethylenediaminetetraacetic acid–trypsin, washed 
twice with phosphate-buffered saline, and subsequently fixed 
with 1% paraformaldehyde for 40 minutes. After blocking with 
1% bovine serum albumin for 1 hour, the cells were stained with 
a 100-fold dilution of participant sera or with phosphate-buff-
ered saline for 2 hours. Binding of human IgG to cells was 
detected with Alexa Fluor 633–conjugated goat anti-human 
IgG (Invitrogen). The median fluorescence intensity of the cells 
was determined with an LSRII HTS flow cytometer (BD). The 
specific binding of human IgG to cells that express RSV SH was 
calculated as the ratio of the Alexa Fluor 633 median fluores-
cence intensity (MFI) of GFP-positive cells and the Alexa Fluor 
633 MFI of GFP-negative cells.
Sample Size and Statistical Analysis
This was a first-in-humans study, and therefore there were 
no previous estimates of the frequency of AEs or of immune 
responses. As the primary outcome was safety, the sample size 
was based on the likely precision around estimates of the per-
centage of participants in each study vaccine group with symp-
toms following vaccination. For example, AEs occurring in 
DPX-RSV(A) group G1 (n = 16) at a rate of ≥15% were detect-
able with a probability >.93, while AEs occurring in one of the 
other comparison groups (8 participants each) at a rate of ≥15% 
will be detectable with a probability >.73. No formal power cal-
culation was conducted. The precision of AE frequency was 
estimated on the basis of standard deviations of estimated pro-
portions for combined sample sizes of 8 or 16, with the true AE 
rate probability between .05 and .50. The expected width of the 
95% CI on the true rate is approximately twice the tabulated 
standard deviation. The frequency of demographic characteris-
tics of participants was described. The safety analysis presented 
here was conducted on the total vaccinated cohort, defined as 
all participants who received at least 1 dose of study vaccine.
The percentages of participants with at least 1 AE, grade 3 
AE, or serious AE following vaccine receipt were tabulated, 
each with an exact 95% CI, and the number and percentage of 
participants with a hematologic or biochemistry result below or 
above the local laboratory range was tabulated. Unsolicited AEs 
were classified and coded according to the Medical Dictionary 
for Regulatory Activities (MedDRA), version 19.0.
Fisher exact tests were used to assess differences in rates of 
solicited AEs. All statistical tests performed were 2-sided with 
a type I error of 5%. No adjustments were made for performing 
multiple tests.
For the analysis of proportions, binomial point estimates 
and exact binomial confidence intervals (CIs) were calculated 
for each group, and differences between groups were compared 
using Fisher exact tests. The analysis of continuous variables 
consisted of point estimates and interval estimates for means, 
and differences between groups were assessed using t tests and 
analysis of variance.
Geometric mean antibody titers (GMTs) and their 95% CIs 
were calculated by group for each time point after vaccination. CIs 
for the difference of geometric means were calculated for the pair-
wise comparison of groups. For each participant, the antibody 
titer was defined as the inverse of the highest dilution (starting 
at 1:100) of postvaccination serum above the cutoff, which was 
determined for each subject on the basis of the day 0 titer. Serum 
samples below the detection limit were assumed to have an anti-
body titer of 50. These analyses were performed using statistical 
and summarization procedures in SAS, version 9.4 (Cary, NC).
For the repeated measurement analysis, log-transformed 
ratios of GFP-positive cells to GFP-negative cells were analyzed 
as repeated measurements, using the residual maximum like-
lihood approach as implemented in Genstat, version 18 [12]. 
Briefly, a linear mixed model with treatment, time, and the 
treatment × time interaction as fixed terms and subject time as a 
residual term was fitted to data. Times of measurement were set 
at unequal intervals, and the unstructured correlation structure 
was selected as the best model fit, based on the Akaike infor-
mation coefficient. Significances of the fixed terms and signifi-
cances of changes in differences between treatment effects over 
time were assessed by an F test.
RESULTS
Forty participants received the first dose of vaccine (Figure 1). 
The investigator withdrew 1 participant at the time of the sec-
ond dose because of new-onset cutaneous herpes zoster. After 
data lock, this subject was noted to be in the placebo group. On 
preordained review of immunogenicity results for participants 
in step 1 by the data safety monitoring committee, the second 
dose of vaccine at day 56 in the RSV(A)-Alum group was pla-
cebo, rather than RSV(A)-Alum. Characteristics of study par-
ticipants are seen in Table 1.
Safety and Reactogenicity
There were no serious AEs or potential immune-mediated dis-
eases, and no holding rule was met during the study. The most 
common local AE was pain (Figure 2); no redness or swelling 
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Figure 2. Percentage of participants with solicited injection site and general adverse events on days 0–6 after vaccination (doses 1 and 2 at days 0 and 56). Grade 3 (severe) 
pain was defined as pain that is significant at rest and prevents normal everyday activities. Redness and swelling were considered present if the greatest surface diameter 
of each was >100 mm. Grade 3 (severe) systemic adverse events were defined as those that prevent normal everyday activities. aParticipants in the RSV(A)-Alum group 
received placebo on day 56, rather than RSV(A)-Alum. See “Methods” for a description of vaccine formulations. DPX, DepoVax; RSV(A), respiratory syncytial virus subgroup A.
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was observed in any study group. All but 1 participant who 
reported pain had mild (grade 1) pain. One participant in the 
25-µg DPX-RSV(A) group reported having moderate (grade 
2) pain for 1 day after the second dose. Pain was less common 
after the second dose.
Any systemic or general AE was reported in 25.0% of par-
ticipants after the first dose and in 21.0% after the second dose, 
with all but 2 of these events being mild in severity. Muscle 
aches and drowsiness were the most commonly reported sys-
temic AEs (Figure 2). The severe AEs were diarrhea (duration, 
24 hours) on day 4 after the first 25-µg dose of RSV(A)-Alum 
and muscle aches (duration, 48 hours) within 24 hours after the 
second 25-µg dose of DPX-RSV(A).
Unsolicited AEs were reported by 37.5%–75.0% of partici-
pants after dose 1 and by 25%–57% after dose 2; the incidence 
was similar across groups, by MedDRA category. Five unsolic-
ited AEs in four participants were graded as severe (ie, grade 3) 
in intensity and were as follows: pneumonia and anemia post 
dose 2 (placebo recipient), migraine post dose 1 (RSV(A)-Alum 
25 µg); diarrhea post dose 1 (DPX-RSV(A)  25 µg) and exac-
erbation of shoulder osteoarthritis post dose 2 (DPX-RSV(A) 
25 mg).
Immunogenicity
DPX-RSV(A) vaccines elicited robust anti-SHe immune 
responses by day 56, which continued to increase to day 236 
(Table  2 and Figure  3). DPX-RSV(A) vaccines had 10-fold 
higher geometric mean antibody titer ratios (GMTRs), com-
pared with placebo, at day 56, and almost 100-fold higher 
GMTRs at day 236 (day 236 GMT, 5381.74 [95% CI, 866.82–
33 413.1; GMTR, 98.69] in the 10-µg DPX-RSV[A] group and 
5381.74 [95% CI, 543.94–53 246.8; GMTR, 98.69] in the 25-µg 
DPX-RSV[A] group).
In exploratory analysis, a statistically significant difference 
in immune response to DPX-RSV(A) vaccines as compared 
to placebo was seen on days 56, 84, and 236. Serum anti-SHe 
responses to Alum-adjuvanted RSV(A) vaccines were poor, like 
placebo.
We also analyzed whether the SHe-specific antibodies 
induced by immunization with DPX-RSV(A) could bind to 
the antigen in its natural context (ie, at the surface of mamma-
lian cells expressing SHe). Flow cytometry showed that, before 
vaccination, there was no or very low binding to cells express-
ing SH (Figure  4 and Supplementary Figure  1). Vaccination 
with placebo or RSV(A)-Alum also resulted in little binding. 
In contrast, IgG in serum samples from recipients of DPX-
RSV(A) displayed significantly enhanced binding to SH on 
the surface of SH-transfected cells (Figure 4), and in individu-
als in the 25-µg DPX-RSV(A) group this persisted for at least 
421 days after the first dose. Overall, there was a clear corre-
lation between the level of SHe-specific antibodies as detected 
by peptide-specific ELISA and the ability of human sera to 
bind to SH expressed at the surface of cells (Supplementary 
Figure 1).
DISCUSSION
In this first-in-humans study, a depot-based lipid-in-oil platform 
formulated with a novel RSV antigenic target was highly immu-
nogenic in healthy adults 50–64  years of age, with sustained 
antigen-specific antibody responses up to 180  days after the 
second vaccine dose and to 421 days in the higher-dose group. 
Alum-adjuvanted vaccines with the RSV SHe antigen performed 
poorly and were not different to placebo. Antibody titers con-
tinued to increase from day 28 to day 56 in both DPX-RSV(A) 
groups, suggesting ongoing antigen presentation at the injection 
site that continued to stimulate the immune response. In pre-
clinical studies in which this adjuvant platform and test antigen 
were visualized with magnetic resonance imaging, the injected 
material could be found in muscle and draining lymph nodes 
for weeks to months after administration [13]. The response to 
Table 1. Characteristics of Participants
Characteristic
DPX-RSV(A)  
(10 µg) (n = 8)
RSV(A)-Alum  
(10 µg) (n = 8)
DPX-RSV(A)  
(25 µg) (n = 8)
RSV(A)-Alum  
(25 µg) (n = 8) Placebo (n = 8) Total (n = 40)
Age, y
 Mean ± SD 56.4 ± 4.84 53.4 ± 3.54 56.3 ± 3.99 56.1 ± 3.64 54.3 ± 3.77 55.3 ± 3.97
 Range 50–63 (50,60) (51,62) (53,63) (50,61)
Sex, no. (%)
 Male 1 (12.5) 5 (62.5) 2 (25.0) 1 (12.5) 2 (25.0) 11 (27.5)
 Female 7 (87.5) 3 (37.5) 6 (75.0) 7 (87.5) 6 (75.0) 29 (72.5)
Race, no. (%)
 Black/African 
Canadian
0 (0) 0 (0) 0 (0) 1 (12.5) 0 (0) 1 (2.5)
 White 8 (100) 8 (100) 8 (100) 7 (87.5) 7 (87.5) 38 (95.0)
 Other 0 (0) 0 (0) 0 (0) 0 (0) 1 (12.5) 1 (2.5)
Data are no. (%) of participants, unless otherwise indicated. See “Methods” for a description of vaccine formulations.
Abbreviations: DPX, DepoVax; RSV(A), respiratory syncytial virus subgroup A.
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the booster dose was robust in both the 10-μg and 25-μg dose 
groups. At day 84, the anamnestic response to the 25-μg dose 
was higher than that to the 10-μg dose, but at day 236 they were 
both about 100-fold higher than in placebo recipients.
The RSV genome encodes 3 surface glycoproteins: F (fusion), 
G (attachment glycoprotein), and SH. RSV vaccine development 
to date has predominately focused on generating an immune 
response to F [14] because it is essential for infection, it is the pri-
mary target for serum neutralizing antibodies, and titers of anti-F 
RSV antibody correlate in many circumstances with protection 
from infection. Unlike G, F is conserved between RSV isolates. 
Further, prophylactic use of the humanized mouse monoclonal 
antibody palivizumab, which is directed at F, reduced the inci-
dence of RSV-associated hospitalization in infants [15]. SH is a 
novel target for a RSV vaccine, and this study is the first to report 
results of a single-subunit SHe-based vaccine study in humans. SH 
is a small protein that comprises 64 and 65 amino acids in sub-
group A and B RSV, respectively [16]. Recent evidence suggests 
Table 2. Geometric Mean Antibody (Ab) Titers to Respiratory Syncytial Virus Subgroup A (RSV[A]) Small Hydrophobic Protein Ectodomain (SHe) Antigen 
Among Recipients of Alum- or DepoVax (DPX)–Adjuvanted RSV(A) SHe Vaccine
Study Day, Group Participants, No.
Ab Titer
GMTR (Specified  
Group: Placebo Group)
Pa
GM Median (95% CI)
RSV(A)-Alum 
(10 µg)
DPX-RSV(A) 
(25 µg)
RSV(A)-Alum 
(25 µg) Placebo
Day 7
 DPX-RSV(A) (10 µg) 8 50 50 (50–50) 1.00 .796 .128 1 1
 RSV(A)-Alum (10 µg) 8 54.53 50 (44.42–50) 1.09 .202 .796 .796
 DPX-RSV(A) (25 µg) 8 84.09 50 (24.6–66.92) 1.68 .128 .128
 RSV(A)-Alum (25 µg) 8 50 50 (50–287.48) 1.00 1
 Placebo 8 50 50 (50–50) NA
Day 28
 DPX-RSV(A) (10 µg) 8 100 50 (19.42–515.02) 1.30 .411 .556 .637 .723
 RSV(A)-Alum (10 µg) 8 54.53 50 (44.42–66.92) 0.71 .162 .723 .637
 DPX-RSV(A) (25 µg) 8 154.22 50 (25.38–937.16) 2.00 .292 .348
 RSV(A)-Alum (25 µg) 8 70.71 50 (38.06–131.38) 0.92 .906
 Placebo 8 77.11 50 (27.68–214.78) NA
Day 56b
 DPX-RSV(A) (10 µg) 8 518.74 282.84 (49.09–5481.28) 10.37 .107 1 .076 .025
 RSV(A)-Alum (10 µg) 8 100 50 (24.18–413.48) 2.00 .107 .863 .491
 DPX-RSV(A) (25 µg) 8 518.74 200 (58.12–4629.83) 10.37 .076 .025
 RSV(A)-Alum (25 µg) 8 84.09 50 (24.6–287.48) 1.68 .605
 Placebo 8 50 50 (50–50) NA
Day 63
 DPX-RSV(A) (10 µg) 8 951.37 1131.37 (102.48–8832.1) 7.07 .058 .866 .019 .072
 RSV(A)-Alum (10 µg) 8 129.68 50 (33.69–499.22) 0.96 .083 .613 .972
 DPX-RSV(A) (25 µg) 8 800 565.69 (97.89–6538.25) 5.94 .028 .1
 RSV(A)-Alum (25 µg) 8 77.11 50 (27.68–214.78) 0.57 .6
 Placebo 7 134.59 50 (26.98–671.45) NA
Day 84
 DPX-RSV(A) (10 µg) 8 2467.54 4525.48 (248.42–24 509.7) 49.35 <.001 .086 <.001 <.001
 RSV(A)-Alum (10 µg)c 8 91.7 50 (27.15–309.68) 1.83 <.001 .922 .497
 DPX-RSV(A) (25 µg) 8 11 737.7 12 800 (2317.1–59 459) 234.75 <.001 <.001
 RSV(A)-Alum (25 µg)c 8 84.09 50 (24.6–287.48) 1.68 .56
 Placebo 8 50 50 (50–50) NA
Day 236
 DPX-RSV(A) (10 µg) 8 5381.74 6400 (866.82–33 413.1) 98.69 <.001 1 <.001 <.001
 RSV(A)-Alum (10 µg)c 8 50 50 (50–50) 0.92 <.001 .748 .915
 DPX-RSV(A) (25 µg) 8 5381.74 6400 (543.94–53 246.8) 98.69 <.001 <.001
 RSV(A)-Alum (25 µg)c 8 64.84 50 (35.07–119.89) 1.19 .83
 Placebo 8 54.53 50 (44.42–66.92) NA
See “Methods” for a description of vaccine formulations. Recipients received 2 doses of vaccine or placebo (one on day 0 and another on day 56).
Abbreviations: CI, confidence interval; GM, geometric mean; GMTR, geometric mean titer ratio; NA, not applicable.
aValues <.05 are statistically significant.
bSerum specimens were procured on day 56, before the second dose of vaccine was given.
cNote that participants in the RSV(A)-Alum group received placebo, rather than RSV(A)-Alum, on day 56.
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that SH can function as a viroporin [17, 18], a small viral mem-
brane protein forming oligomers that act as proton or ion chan-
nels in the host cell and, thus, enhance membrane permeability. 
In vitro studies showed that SH inhibits apoptosis by blocking 
a tumor necrosis factor–mediated signaling pathway [19]. SH 
could thus promote viral replication by interfering with the host 
immune response and prolong viral replication in the host cell 
[20]. In preclinical studies in mice and cotton rats, SHe-vaccinated 
and intranasally challenged animals had reduced RSV replication, 
and SHe-specific antibodies were detected bound to the surface 
of RSV-infected cells [8]. Further, SHe-specific immune serum 
reduced replication in the lung in a dose-dependent manner. In 
Figure 4. Binding of serum immunoglobulin G (IgG) to respiratory syncytial virus (RSV) small hydrophobic protein (SH) on the surface of cells. DPX-RSV(A) vaccination of 
human volunteers induces serum IgG that can bind to cells expressing the RSV SH surface protein. HEK293T cells coexpressing RSV SH and green fluorescent protein (GFP; 
Hek-SH) were analyzed by flow cytometry for human IgG binding, using sera sampled at the indicated time points after the last immunization with placebo, RSV(A)-Alum, or 
DPX-RSV(A). Data denote the ratio of the mean fluorescence intensity (MFI) of cells expressing SH (ie, GFP-positive cells) to the MFI of control cells (ie, GFP-negative cells) in 
individual serum samples. Short horizontal lines represent mean values. A, Data from low-dose (step 1) vaccine recipients. B, Data from high-dose (step 2) vaccine recipients. 
See “Methods” for a description of vaccine formulations. DPX, DepoVax.
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A booster dose was administered on day 56. See “Methods” for a description of vaccine formulations. DPX, DepoVax.
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the mouse model, this protection was strictly dependent on acti-
vating Fcγ receptors and on resident alveolar macrophages. As 
such, it was hypothesized that SHe-specific IgG can control RSV 
replication by inducing resident alveolar macrophages to clear 
RSV-infected cells by phagocytosis. The very high anti-SHe anti-
body titers in recipients of the lipid-in-oil adjuvanted RSV vaccine 
suggest that this may be a valid vaccination strategy targeting this 
viral protein.
The study lipid-in-oil adjuvant has been shown in preclini-
cal studies to produce a strong, specific, and sustained immune 
response [21–23] and has been evaluated in phase 1 studies of 
2 DepoVax-formulated therapeutic cancer vaccines, DPX-0907 
[24] and DPX-Survivac [25]. In these studies of patients with 
advanced ovarian, breast, and prostate cancers, in which a consid-
erably higher dose volume of the platform is used, an acceptable 
safety profile and specific immune responses have been observed. 
The DPX-RSV(A) formulation was also administered in a very 
small volume (0.05 mL [50 µL]), which to our knowledge is the 
lowest volume ever reported for an oil-based vaccine in humans. 
Injecting this small volume may reduce local adverse events.
This study has several limitations. It is a first-in-humans study 
designed with a small sample size to minimize exposure of par-
ticipants to a novel vaccine. Infrequent AEs may not have been 
detected and might occur at time points later than the follow-up 
period of this study. Given that our vaccine is targeted at older 
adults, it was conducted in individuals aged 50–64 years. Although 
our study population was older than that in most phase 1 trials, 
which are often conducted in individuals aged 18–40 years, the 
vaccine was not evaluated in the target age group of ≥65 years. 
Accordingly, results may not be applicable to that population. 
Further study in persons >65  years of age is therefore needed. 
Finally, our vaccine antigen contained a synthetic RSV-A anti-
gen, SHe. Since there is variability in the sequence homology of 
SHe across RSV A and B subgroups [26], a SHe-containing RSV 
vaccine would likely need to contain both subgroup antigens.
In summary, in this first-in-humans study a depot-based 
lipid-in-oil adjuvant platform copresented with a novel RSV 
antigenic target was safe and highly immunogenic in adults 
50–64  years of age, with sustained humoral responses up to 
180 days after vaccination.
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